



#10  
Dd  
5/30/01

PATENT  
ATTORNEY DOCKET NO. 50010/007006

Certificate of Mailing: Date of Deposit: <u>May 17, 2001</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as <b>first class mail</b> with sufficient postage on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Susan M. Barry</u> Printed name of person mailing correspondence	<u>Susan M. Barry</u> Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Richard F Selden <i>et al.</i>	Art Unit:	1636
Serial No.:	09/328,130	Examiner:	R. Schwartzman
Filed:	June 8, 1999	Customer No.:	21559
Title:	<i>In Vivo</i> Production and Delivery of Erythropoietin or Insulinotropin for Gene Therapy		

Assistant Commissioner For Patents  
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

In reply to the Office Action that was mailed in the above-captioned case on January 17, 2001, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of two pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing is now being added to the application after the Combined Declaration and Power of Attorney.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

1. ANALYSIS STATEMENT: [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]